- Home
- CRIS vs CGTX Comparison
CRIS vs CGTX Comparison
Compare CRIS & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- CGTX
- Stock Information
- Founded
- CRIS 2000
- CGTX 2007
- Country
- CRIS United States
- CGTX United States
- Employees
- CRIS N/A
- CGTX N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- CRIS Health Care
- CGTX Health Care
- Exchange
- CRIS Nasdaq
- CGTX Nasdaq
- Market Cap
- CRIS 32.8M
- CGTX 17.2M
- IPO Year
- CRIS 2000
- CGTX 2021
- Fundamental
- Price
- CRIS $2.77
- CGTX $0.43
- Analyst Decision
- CRIS Strong Buy
- CGTX Strong Buy
- Analyst Count
- CRIS 3
- CGTX 6
- Target Price
- CRIS $23.00
- CGTX $8.30
- AVG Volume (30 Days)
- CRIS 29.9K
- CGTX 2.8M
- Earning Date
- CRIS 05-06-2025
- CGTX 05-06-2025
- Dividend Yield
- CRIS N/A
- CGTX N/A
- EPS Growth
- CRIS N/A
- CGTX N/A
- EPS
- CRIS N/A
- CGTX N/A
- Revenue
- CRIS $10,259,000.00
- CGTX N/A
- Revenue This Year
- CRIS N/A
- CGTX N/A
- Revenue Next Year
- CRIS N/A
- CGTX N/A
- P/E Ratio
- CRIS N/A
- CGTX N/A
- Revenue Growth
- CRIS 0.44
- CGTX N/A
- 52 Week Low
- CRIS $2.57
- CGTX $0.34
- 52 Week High
- CRIS $17.49
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- CRIS 30.63
- CGTX 25.38
- Support Level
- CRIS $2.57
- CGTX $0.36
- Resistance Level
- CRIS $3.15
- CGTX $0.45
- Average True Range (ATR)
- CRIS 0.16
- CGTX 0.05
- MACD
- CRIS -0.03
- CGTX -0.01
- Stochastic Oscillator
- CRIS 13.11
- CGTX 17.03
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.